Enhancing Social Competence in Adults With Autism

Autism Spectrum Disorder Clinical Trial

Official title:

Enhancing Social Competence in Adults With Autism Spectrum Disorder: A Pilot RCT

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04349644
• Other study ID #: 192271
• Secondary ID: 1R33MH120149-01A
• Status: Active, not recruiting
• Phase: N/A
• Start date: October 21, 2020
• Est. completion date: March 30, 2025

Study information

• Verified date: March 2024
• Source: Vanderbilt University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

SENSE Theatre®, combines several well-documented, effective behavioral strategies, such as the inclusion of trained peer models, theatre play techniques involving predictable (i.e., scripted) and flexible (improvised) role-play, and repeated performance of newly learned skills resulting in greater automaticity of behavior. The intervention has the potential to enhance social cognition and behavior in adults with autism spectrum disorder.

Description:

Autism spectrum disorder (ASD) is characterized by primary impairment in social competence. Effects of current psychosocial interventions often fail to maintain or generalize and few employ rigorous experimental methods. Our treatment, SENSE Theatre®, combines several well-documented, effective behavioral strategies, such as the inclusion of trained peer models, theatre play techniques involving predictable (i.e., scripted) and flexible (improvised) role-play, and repeated performance of newly learned skills resulting in greater automaticity of behavior. Recent findings from a randomized control trial (RCT) show immediate between-group effects and evidence of target engagement on the hypothesized mechanism of action, memory for faces, which was evaluated by neuropsychological and event-related potential (ERP) measures. Moreover, the RCT demonstrated treatment effects on social communication skills that generalized to home and community settings. Finally, maintained treatment effects were observed on communication symptoms. The proposed project will extend these findings and provide a stronger test of efficacy using an RCT of SENSE Theatre with a sample of approximately 40 adult participants with ASD (18 to 35 years) randomized to experimental (EXP; N = 20) and a wait list control group (WLC; N = 20) in two separate cohorts. The RCT will assess target engagement of memory for faces and functional change in social interaction with peers using examiners blind to study treatment group assignment. The significance and size of treatment effects on these cognitive and behavioral outcomes will be measured using ANOVA and linear mixed models. Thus, the overarching aim of the study is to determine whether detected changes in face memory and social interaction are due to the SENSE Theatre® treatment and the extent to which these changes generalize and maintain. If predicted results occur, it will provide strong empirical support for a community-based treatment that has generalized effects on a set of core deficits that otherwise have life-long consequences for adults with ASD.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 73
• Est. completion date: March 30, 2025
• Est. primary completion date: March 15, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 35 Years

Eligibility

ASD Inclusion Criteria:

• diagnosed with ASD based on DSM-V criteria (APA, 2013), by a psychologist, pediatrician or psychiatrist with expertise in ASD will be enrolled. ASD diagnosis will be corroborated by the Autism Diagnostic Observation Schedule (ADOS-2) (Lord, 2012).
• Only adults not currently supported by educational opportunities will be enrolled.
• Participants must have a full-scale IQ > or = 70 (WASI; (Wechsler, 2011))

ASD Exclusion Criteria:

• Adults with intellectual impairment (WASI; (Wechsler, 2011) score < 70.
• Participants with current, frequent and uncontrolled aggression toward other persons or property in the past 6 months will be excluded based on phone screening and questions from the Adult Behavior Checklist (Achenbach, 2001) (e.g., "Physically attacks people").
• Participants with evidence of suicidality based on care-provider report, self-report, or clinical interview (i.e., endorsement of suicidal ideation in the past month and/or suicidal behavior in the past three months on the Columbia Suicide Severity Rating Scale (Posner, 2011),
• Previous SENSE Theatre® participants will be excluded.

Care-giver Inclusion Criteria:

• must be at least 18 years of age
• must be a parent, close relative, or spouse of the adult participant with ASD.
• must be able to provide current and historical observations of the functioning of the participant with ASD.
• must live in close proximity to and have frequent contact with the participant with ASD.

Care-giver Exclusion Criteria:

• Anyone not meeting inclusion criteria.

Confederates Inclusion Criteria:

• must be at least 18 years of age
• typically developing individual with no neurodevelopmental disorder.
• must successfully complete training and demonstrate consistent administration of research protocols.

Confederate Exclusion Criteria:

• Anyone not meeting inclusion criteria.

Peers Inclusion Criteria:

• must be at least 18 years of age
• typically developing individual with no neurodevelopmental disorder.
• must have an expressed interest in supporting young adults and adults with developmental disabilities or ASD
• must successfully complete SENSE Theatre® training.

Peers Exclusion Criteria:

• Anyone not meeting inclusion criteria.

Related Conditions & MeSH terms

• Autism Spectrum Disorder
• Autistic Disorder

Intervention

Behavioral:
• SENSE Theatre
A peer-mediated, theatre-based intervention that involves 10 sessions of approximately 3 hours each that culminates in a public performance.

Locations

Country	Name	City	State
United States	Vanderbilt University Medical Center	Nashville	Tennessee

Sponsors (2)

Lead Sponsor	Collaborator
Vanderbilt University Medical Center	National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Incidental Face Memory	An event-related Potential Task that presents 51 novel faces and 51 novel houses one of each is randomly selected and presented 50 times (repeated). We are examining an increase in amplitude of 250-500 ms time window between the repeated and single face presentation. Positive values indicate better face memory.	Pretest to Week 11
Primary	Change in Contextual Assessment of Social Skills	An observational assessment measure of social cognition and communication which includes two 3-minutes conversations with typically developing peers showing interested or bored demeanor. The behaviors are rated based on raw scores on a likert scale from 1 to 7 with 7 reflecting better ability.	Pretest to Week 11
Primary	Change in Social Responsiveness Scale - Self (SRS)	The SRS is a standardized measure of social competence administered by participants pertaining to behaviors characteristic of adults with ASD. T-scores range from scores of 38 to 90 with higher scores reflecting greater impairment.	Pretest to Week 11
Primary	Change in Social Responsiveness Scale - Parent (SRS)	The SRS is a standardized measure of social competence administered by care-givers pertaining to behaviors characteristic of adults with ASD. T-scores range from scores of 38 to 90 with higher scores reflecting greater impairment.	Pretest to Week 11
Secondary	Cambridge Face Memory Test	A standardized measure of face memory with 72 items. Any increase in the raw score pertaining to the number of faces identified constitutes an increase in face memory.	Pretest, Week 11, two-month follow-up
Secondary	Wechsler Memory Scale Face Memory Delay Test	A standardized measure of face memory in which the participant is exposed to 24 faces in which they must remember amidst an array of 48 faces presented immediately and after a 30-minute delay. Any increase in the raw score pertaining to the number of faces identified constitutes an increase in face memory.	Pretest, Week 11, two-month follow-up
Secondary	Wechsler Memory Scale Face Memory Test	A standardized measure of face memory in which the participant is exposed to 24 faces in which they must remember amidst an array of 48 faces presented immediately and after a 30-minute delay. Any increase in the raw score pertaining to the number of faces identified constitutes an increase in face memory.	Pretest, Week 11, two-month follow-up
Secondary	Adaptive Behavior Assessment System (ABAS) - Self-Report	The ABAS measures adaptive living skills using a Standardized Scale in which scores from 85 to 115 reflect the broad average range. Lower scores represent greater impairment.	Pretest, Week 5, Week 11, two-month follow-up
Secondary	Adaptive Behavior Assessment System (ABAS) - Parent-Report	The ABAS measures adaptive living skills using a Standardized Scale in which scores from 85 to 115 reflect the broad average range. Lower scores represent greater impairment.	Pretest, Week 5, Week 11, two-month follow-up
Secondary	State-Trait Anxiety Inventory (STAI) Scale	The STAI is a measure of current (State) and enduring (Trait) anxiety that is completed by the participant. There are 20 items for each domain on a 4-point scale (1 = Almost Never, 4 = Almost Always) and higher scores reflect greater anxiety.	Pretest, Week 11, two-month follow-up
Secondary	The Adult Self Report (ASR)	The ASR is the self-report of the Achenbach empirically system which covers emotional health. We will focus on the anxiety and depressive subscales. T-scores range from 40 to 100 with higher scores representing more impairment.	Pretest, Week 5, Week 11, two-month follow-up
Secondary	The Adult Behavior Checklist (ABCL)	The ABCL is the care-giver-report version of the Achenbach system that covers emotional health. We will focus on the anxiety and depressive subscales. T-scores range from 40 to 100 with higher scores representing more impairment.	Pretest, Week 5, Week 11, two-month follow-up